ViaNautis Bio

About ViaNautis Bio

ViaNautis is a biotechnology company focused on pioneering the next generation of genetic nanomedicines. They leverage their proprietary polyNaut(r) nanovesicle platform, which uses advanced polymer materials and machine learning, to deliver nucleic acid therapeutics with precision to specific sites of action. Based in Cambridge, UK, ViaNautis aims to revolutionize treatments for previously untreatable diseases through genetic medicines like mRNA, siRNA, and gene editing.

Products & Services

polyNaut(r) Platform:A proprietary nanovesicle technology using advanced polymer materials and in silico screening to deliver genetic therapeutic payloads across biological barriers with high precision.

Specialties

Genetic Nanomedicines Nucleic Acid Therapeutics Nanovesicle Technology Polymer Materials Machine Learning in Drug Delivery

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 25000000 MR: - FA: $25 million FAN: 25000000	D: 2023-11-13 FD: 2023-11-13	8 investors

Series A Latest

2023-11-13

$25.0M

8 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Ray Jupp

Chief Scientific Officer

A

Adi Hoess

Chief Executive Officer

S

Steven M. Altschuler

Chairman of the Board of Directors

Recent News

ViaNautis Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised